These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10784645)

  • 21. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M; Vici P
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.
    Sargent JM; Williamson CJ; Yardley C; Taylor CG; Hellmann K
    Br J Cancer; 2001 Apr; 84(7):959-64. PubMed ID: 11286477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer in older adults: understanding cause and effects of chemotherapy-related toxicities.
    Bhatt VR
    Future Oncol; 2019 Aug; 15(22):2557-2560. PubMed ID: 31339058
    [No Abstract]   [Full Text] [Related]  

  • 24. Overview and historical development of dexrazoxane.
    Hellmann K
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical status and optimal use of the cardioprotectant, dexrazoxane.
    Blum RH
    Oncology (Williston Park); 1997 Nov; 11(11):1669-77; discussion 1677-8, 1681. PubMed ID: 9394365
    [No Abstract]   [Full Text] [Related]  

  • 26. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
    Hasinoff BB
    Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.
    Hoekman K; van der Vijgh WJ; Vermorken JB
    Drugs; 1999 Feb; 57(2):133-55. PubMed ID: 10188757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prenatal effects of the cancer chemotherapeutic drug ICRF 159 in mice, rats, and rabbits.
    Duke DI
    Teratology; 1975 Feb; 11(1):119-26. PubMed ID: 1138404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation.
    Tyson AM; Gay WE
    Ann Pharmacother; 2010 May; 44(5):922-5. PubMed ID: 20371757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
    Pouillart P
    Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recommendations of the Working Group 'Supportive Massnahmen in der Onkologie' concerning the Clinical Use of Cytoprotectives].
    Büntzel J; Bokemeyer C; Wagner W;
    Onkologie; 2001 Feb; 24(1):81-6. PubMed ID: 11441287
    [No Abstract]   [Full Text] [Related]  

  • 32. Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown.
    Hellmann K
    Clin Exp Metastasis; 2003; 20(2):95-102. PubMed ID: 12705630
    [No Abstract]   [Full Text] [Related]  

  • 33. Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation.
    Arroyo PA; Perez RU; Feijoo MA; Hernandez MA
    J Cancer Res Ther; 2010; 6(4):573-4. PubMed ID: 21358106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, Part 2.
    Simone CB; Simone NL; Simone V; Simone CB
    Altern Ther Health Med; 2007; 13(2):40-7. PubMed ID: 17405678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Future development of amifostine as a radioprotectant.
    Werner-Wasik M
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S; Hoffmanns H
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
    Wexler LH
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dexrazoxane: new indication. Anthracycline extravasation: continue using dimethyl sulfoxide.
    Prescrire Int; 2009 Feb; 18(99):6-8. PubMed ID: 19382398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
    Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1.
    Simone CB; Simone NL; Simone V; Simone CB
    Altern Ther Health Med; 2007; 13(1):22-8. PubMed ID: 17283738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.